Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
This additional mechanism makes it a distinct and more complex research target, particularly for labs investigating the intersection of lipolysis, glycemic control, and appetite-regulatory pathways at a molecular level
It has surpassed the effectiveness of Semaglutide (Ozempic + Wegovy), with patients seeing as much as 22.5% body weight loss
See our research use policy.
The downside
The ATTAIN-1 trial reported a mean change in body weight at 72 weeks of -11.2% with the highest dose of orforglipron 36 mg compared to -2.1% with placebo in adults with obesity or overweight and at least one weight-related comorbidity
SEMAGLUTIDE RESULTS Reap the rewards as we progress with regular labs, feedback, and advanced technology to optimize your health and wellness
